Objective: To assess Clostridium difficile infection (CDI)-related colectomy rates by CDI surveillance definitions and over time at multiple healthcare facilities.
Setting: Five university-affiliated acute care hospitals in the United States.
Design And Methods: Cases of CDI and patients who underwent colectomy from July 2000 through June 2006 were identified from 5 US tertiary care centers. Monthly CDI-related colectomy rates were calculated as the number of CDI-related colectomies per 1,000 CDI cases, and cases were categorized according to recommended surveillance definitions. Logistic regression was performed to evaluate risk factors for CDI-related colectomy.
Results: In total, 8,569 cases of CDI were identified, and 75 patients underwent CDI-related colectomy. The overall colectomy rate was 8.7 per 1,000 CDI cases. The CDI-related colectomy rate ranged from 0 to 23 per 1,000 CDI episodes across hospitals. The colectomy rate for healthcare-facility-onset CDI was 4.3 per 1,000 CDI cases, and that for community-onset CDI was 16.5 per 1,000 CDI cases (P < .05). There were significantly more CDI-related colectomies at hospitals B and C (P < .05).
Conclusions: The overall CDI-related colectomy rate was low, and there was no significant change in the CDI-related colectomy rate over time. Onset of disease outside the study hospital was an independent risk factor for colectomy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3657463 | PMC |
| http://dx.doi.org/10.1086/665318 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical significance of toxin EIA positivity in patients with suspected infection: systematic review and meta-analysis.
J Clin Microbiol
December 2024
Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, Washington, USA.
The laboratory diagnosis of infection (CDI) is controversial. Nucleic acid amplification tests (NAAT) and toxin enzyme immunoassays (EIA) are most widely used, often in combination. However, the interpretation of a positive NAAT and negative toxin immunoassay (NAAT+/EIA-) is uncertain.
View Article and Find Full Text PDFFactors Associated With Fecal Microbiota Transplant Failure in the Treatment of Recurrent Clostridioides difficile Infection: A Single-Center Retrospective Study.
Cureus
September 2023
Infectious Disease, University of Massachusetts Chan Baystate Medical Center, Springfield, USA.
Background infection (CDI) is a major cause of hospital-acquired diarrhea and is associated with substantial morbidity and mortality. Recurrences following treatment are common. Fecal microbiota transplantation (FMT) is a therapeutic intervention in which stool from a healthy donor is administered to a patient with recurrent CDI.
View Article and Find Full Text PDFA Predictive Model to Identify Complicated Infection.
Open Forum Infect Dis
February 2023
Division of Infectious Diseases, University of Michigan, Ann Arbor, Michigan, USA.
Background: infection (CDI) is a leading cause of health care-associated infection and may result in organ dysfunction, colectomy, and death. Published risk scores to predict severe complications from CDI demonstrate poor performance upon external validation. We hypothesized that building and validating a model using geographically and temporally distinct cohorts would more accurately predict risk for complications from CDI.
View Article and Find Full Text PDFOutcomes of Continuous Enteral Vancomycin Infusion in Intensive Care Unit Patients: A Novel Treatment Modality for Severe Clostridium Difficile Colitis.
Cureus
March 2022
Pulmonary & Critical Care, Indiana University School of Medicine, Indianapolis, USA.
Background and objective Severe infection (CDI)-related colitis is associated with high morbidity and mortality. Current guidelines recommend oral vancomycin plus intravenous metronidazole as the first-line treatment and early total colectomy in case of medication failure. In critically ill patients at high surgical risk and with multiple comorbidities, loop ileostomy creation and enteral vancomycin infusion have been employed albeit with limited success.
View Article and Find Full Text PDFP074 Comparative Risk of Clostridioides Difficile Infection in Vedolizumab vs anti-TNFa Agents in Biologic-Naïve Patients With Ulcerative Colitis.
Am J Gastroenterol
December 2021
Brigham and Women's Hospital, Boston, Massachusetts, United States.
Article Synopsis
- The study investigates the risk of Clostridioides difficile infection (CDI) in ulcerative colitis (UC) patients on vedolizumab compared to those on anti-TNFα agents like infliximab and adalimumab.
- It is a retrospective cohort study involving adult UC patients from a large academic health system, excluding individuals with certain other conditions and prior biologic treatments.
- The main outcome measured is the time to first CDI after starting treatment, with secondary outcomes including hospitalization and other complications related to CDI.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!